Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
The vital Rafah border crossing between Gaza and Egypt reopened Monday for strictly limited passenger traffic, marking a tentative step in the implementation of the Israel-Hamas ceasefire. The move, described as largely symbolic for now, offers a glimmer of hope for thousands of Palestinians seeking medical care or a return home.
As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.
The Rafah border crossing between Gaza and Egypt reopened Monday for strictly limited passenger traffic, marking a critical, if symbolic, step in implementing the U.S.-brokered ceasefire. The move follows intense diplomatic efforts and comes as the agreement enters a more complex second phase.
Israel is set to partially reopen the Rafah border crossing with Egypt, allowing limited pedestrian movement for Palestinians. The move, a condition of the U.S.-brokered ceasefire, comes amid ongoing tensions and a continued ban on foreign journalists.
Exelixis shares have delivered impressive multi-year returns, but recent price weakness has investors questioning if the rally has run its course. A deep dive into valuation models suggests the stock may still be significantly undervalued, presenting a potential opportunity amidst market uncertainty.
Amidst a cautiously optimistic Asian market, companies where executives and directors hold significant stakes are drawing investor attention. We examine three high-conviction plays in semiconductors, 3D printing, and biotech where insider ownership aligns with explosive growth forecasts.
IDEAYA Biosciences shares have retreated from recent highs, presenting investors with a dilemma. While long-term performance remains strong, its premium valuation and significant net losses raise questions about whether the current price already reflects its promising pipeline.
Israel announces a limited, security-heavy reopening of Gaza's Rafah crossing with Egypt, allowing some medical evacuations while concerns mount over aid access and the safety of returnees.
BeOne Medicines (NasdaqGS: ONC) has significantly expanded its strategic partnership with systems biology firm InSysBio. The deepened collaboration aims to leverage advanced mechanistic modeling to de-risk clinical trial design, with a particular focus on optimizing dosing and preempting safety challenges like cytokine release syndrome in oncology studies.
As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.
In an exclusive interview, Robert F. Kennedy Jr. addresses the state of his relationship with cousin Caroline Kennedy following the death of her daughter, Tatiana Schlossberg, last December. The tragedy unfolds against a backdrop of deep political rifts within America's most storied political dynasty.
Health and Human Services Secretary Robert F. Kennedy Jr. has publicly addressed the deep divisions within America's most storied political family, following the death of his cousin Tatiana Schlossberg and amidst ongoing policy controversies that have placed him at odds with his relatives.
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
After a bruising year that saw its shares tumble by a third, biotech giant CSL is back in the spotlight. We delve beyond the headline numbers, examining valuation models and market sentiment to assess if the sell-off has created a compelling entry point for long-term investors.
Galderma Group's (SWX:GALD) shares have faced significant pressure in recent months, contrasting sharply with its strong yearly performance. This analysis delves into whether the current valuation presents a genuine entry point or reflects deeper concerns about the dermatology giant's ambitious growth narrative.
Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Robust cash generation is a hallmark of financial health, but it doesn't guarantee future performance. We examine three companies with strong free cash flow margins whose underlying challenges—from competitive pressures to growth concerns—suggest investors should look closer before buying.
